A detailed history of Glenmede Trust CO Na transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Glenmede Trust CO Na holds 943,271 shares of BMY stock, worth $55.5 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
943,271
Previous 1,239,711 23.91%
Holding current value
$55.5 Million
Previous $51.5 Million 5.19%
% of portfolio
0.24%
Previous 0.26%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $11.8 Million - $15.3 Million
-296,440 Reduced 23.91%
943,271 $48.8 Million
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $5.36 Million - $7.05 Million
-133,064 Reduced 9.69%
1,239,711 $51.5 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $1.7 Million - $1.93 Million
-35,413 Reduced 2.51%
1,372,775 $74.4 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $7.96 Million - $9.5 Million
164,182 Added 13.2%
1,408,188 $72.3 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $21 Million - $23.5 Million
-362,524 Reduced 22.57%
1,244,006 $72.2 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $28,542 - $31,691
-448 Reduced 0.03%
1,606,530 $103 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $711,245 - $806,712
10,824 Added 0.68%
1,606,978 $111 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $1.11 Million - $1.31 Million
-16,143 Reduced 1.0%
1,596,154 $115 Million
Q3 2022

Nov 16, 2022

BUY
$0.13 - $76.84 $1,102 - $651,449
8,478 Added 0.53%
1,612,297 $115 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $12.3 Million - $13.5 Million
169,230 Added 11.8%
1,603,819 $123 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $248,317 - $297,755
-4,039 Reduced 0.28%
1,434,589 $105 Million
Q4 2021

Feb 15, 2022

SELL
$53.63 - $62.52 $2.97 Million - $3.46 Million
-55,311 Reduced 3.7%
1,438,628 $89.7 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $958,258 - $1.12 Million
-16,195 Reduced 1.07%
1,493,939 $88.4 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $4.18 Million - $4.55 Million
-67,515 Reduced 4.28%
1,510,134 $101 Million
Q1 2021

May 18, 2021

SELL
$59.34 - $66.74 $4.3 Million - $4.84 Million
-72,528 Reduced 4.4%
1,577,649 $99.6 Million
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $118,078 - $133,804
-2,045 Reduced 0.12%
1,650,177 $102 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $549,317 - $608,716
-9,565 Reduced 0.58%
1,652,222 $99.6 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $100 Million - $117 Million
-1,825,581 Reduced 52.35%
1,661,787 $97.7 Million
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $76.8 Million - $100 Million
1,560,071 Added 80.95%
3,487,368 $224 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $9.32 Million - $11 Million
217,842 Added 12.74%
1,927,297 $97.7 Million
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $12.4 Million - $13.8 Million
278,728 Added 19.48%
1,709,455 $77.5 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $35 Million - $41.7 Million
775,266 Added 118.28%
1,430,727 $68.3 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $4.53 Million - $5.87 Million
92,873 Added 16.51%
655,461 $34.1 Million
Q3 2018

Nov 15, 2018

BUY
$55.19 - $62.25 $5.43 Million - $6.13 Million
98,436 Added 21.21%
562,588 $34.9 Million
Q2 2018

Nov 05, 2018

SELL
$50.53 - $62.98 $46.2 Million - $57.6 Million
-913,952 Reduced 66.32%
464,152 $25.7 Million
Q2 2018

Aug 15, 2018

BUY
$50.53 - $62.98 $47.1 Million - $58.7 Million
932,381 Added 209.18%
1,378,104 $76.3 Million
Q4 2017

Feb 15, 2018

BUY
$59.94 - $65.35 $2.67 Million - $2.91 Million
44,579 Added 11.11%
445,723 $27.3 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $22.2 Million - $25.6 Million
401,144
401,144 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Glenmede Trust CO Na Portfolio

Follow Glenmede Trust CO Na and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.